Trexquant Investment LP Boosts Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Trexquant Investment LP boosted its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 895.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 114,480 shares of the biotechnology company’s stock after purchasing an additional 102,980 shares during the period. Trexquant Investment LP owned approximately 0.19% of Aldeyra Therapeutics worth $571,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in Aldeyra Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company’s stock valued at $5,588,000 after buying an additional 4,927 shares during the period. LPL Financial LLC raised its holdings in Aldeyra Therapeutics by 186.2% in the fourth quarter. LPL Financial LLC now owns 59,488 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 38,702 shares in the last quarter. Intech Investment Management LLC lifted its position in Aldeyra Therapeutics by 62.7% during the 4th quarter. Intech Investment Management LLC now owns 23,806 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 9,178 shares during the period. Kennondale Capital Management LLC bought a new stake in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $755,000. Finally, Catalyst Funds Management Pty Ltd boosted its holdings in Aldeyra Therapeutics by 2,083.3% in the fourth quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 12,500 shares in the last quarter. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Trading Up 1.1 %

Shares of Aldeyra Therapeutics stock opened at $1.91 on Friday. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The company has a fifty day moving average of $5.54 and a 200 day moving average of $5.26. Aldeyra Therapeutics, Inc has a fifty-two week low of $1.14 and a fifty-two week high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). On average, equities analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. BTIG Research reduced their price target on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, April 7th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, April 4th.

Insider Transactions at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the company’s stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the sale, the insider now directly owns 5,875,851 shares in the company, valued at $8,343,708.42. This represents a 36.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 8.50% of the company’s stock.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.